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ABSTRACT 
 
Biliary innate immunity is involved in the pathogenesis of cholangiopathies in patients 
with primary biliary cirrhosis (PBC) and biliary atresia. Biliary epithelial cells possess 
an innate immune system consisting of the Toll-like receptor (TLR) family and 
recognize pathogen-associated molecular patterns (PAMPs). Tolerance to bacterial 
PAMPs such as lipopolysaccharides is also important to maintain homeostasis in the 
biliary tree, but tolerance to double-stranded RNA (dsRNA) is not found. In PBC, 
CD4-positive Th17 cells characterized by the secretion of IL-17 are implicated in the 
chronic inflammation of bile ducts and the presence of Th17 cells around bile ducts is 
causally associated with the biliary innate immune responses to PAMPs. Moreover, a 
negative regulator of intracellular TLR signaling, peroxisome proliferator-activated 
receptor-γ (PPARγ), with a Th1-predominant cytokine milieu is involved in the 
pathogenesis of cholangitis. Immunosuppression using PPARγ ligands may help to 
attenuate the bile duct damage in PBC patients. In biliary atresia characterized by a 
progressive, inflammatory, and sclerosing cholangiopathy, dsRNA viruses are 
speculated to be an etiological agent and to directly induce enhanced biliary apoptosis 
via the expression of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). 
Moreover, the epithelial-mesenchymal transition (EMT) of biliary epithelial cells is also 
evoked by the biliary innate immune response to dsRNA.  
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Introduction 
Clarification of the molecular mechanisms of innate immunity and 
significance of innate immune responses to the pathogenesis of immune-mediated 
diseases as well as to defense against infections has progressed steadily since the 
cloning of Tolls in drosophila and Toll-like receptors (TLRs) in mammals including 
humans [1,2]. Innate immunity was initially thought to be limited to 
immunocompetent cells such as dendritic cells and macrophages, but epithelial cells 
also possess TLRs and proper innate immune systems. Liver and extrahepatic bile 
ducts consisting of hepatocytes and biliary epithelial cells (BECs) are also exposed to 
microorganisms and their components originating from the intestines via portal blood 
and duodenum. In the gastrointestinal tract, TLRs expressed in intestinal epithelial 
cells may be involved in innate immunity to maintain mucosal homeostasis and also 
the development of enterocolitis by producing inflammatory molecules [3]. Similar 
processes using TLRs may operate in the biliary tree. Human bile is sterile under 
normal conditions, but bacterial components such as lipopolysaccharide (LPS), 
lipoteichoic acid, and bacterial DNA fragments, known as pathogen-associated 
molecular patterns (PAMPs), are detectable in normal and pathologic bile [4-7] and 
cultivable bacteria are also detectable in bile of patients with inflammatory biliary 
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diseases [8-11], indicating that BECs are exposed to bacterial components under 
physiological as well as pathological conditions (Table 1). Although hepatocytes are 
usually infected by the hepatitis virus, no microorganisms showing BEC-specific 
tropism have been identified. The participation of microorganisms, however, in the 
etiology or pathogenesis of various cholangiopathies and biliary diseases has been 
reported or speculated. In this review, we describe the biliary innate immune system, 
its association with the pathogenesis of cholangiopathy and biliary diseases, and 
finally a strategy for the attenuation of cholangiopathy, particularly cholangitis, by the 
regulation of innate immune responses. 
 
Association with biliary innate immunity in biliary diseases 
Infectious agents have been implicated in the etiology or progression of 
cholangiopathies including cholangitis, bile duct loss, and lithiasis as a trigger or 
aggravating factor. Notably, several enterobacteria and viruses are speculated to be 
primary or secondary factor for primary biliary cirrhosis (PBC), primary sclerosing 
cholangitis, biliary atresia, hepatolithiasis, and chronic cholecystitis [4,5,12-16] (Table 
1).  
Primary biliary cirrhosis (PBC): PBC patients have an increased incidence 
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of recurrent urinary tract infections compared to patients with other chronic liver 
diseases [17-19]. Recent findings also support an association between vaginal or 
urinary tract infections and PBC [20]. Furthermore, endotoxin and lipoteichoic acids 
abnormally accumulate in or around the intrahepatic bile ducts [7,16,21] and DNA of 
Propionibacterium acnes (P. acnes) was detected as a major clone in the granulomas 
of PBC patients (Table 1) [22]. Because these bacterial components, whether proteins 
or nucleic acids, act as PAMPs, the presence of PAMPs in bile or around bile ducts is 
known to induce a variety of inflammatory reactions and speculated to underlie the 
etiopathogenesis of the cholangiopathy in cases of PBC.  
The major autoantigens against antimitochondrial antibodies (AMAs) in PBC 
are members of the 2-oxo-acid dehydrogenase complex (2-OADC), which includes 
the E2 subunit of the pyruvate dehydrogenase complex (PDC-E2) [23]. An immune 
response to intrahepatic BECs through 2-OADC-specific CD4+ helper T cells and 
CD8+ cytotoxic T cells is thought to be the major mechanism responsible for the 
immunological destruction of BECs in PBC and these T cells show molecular mimicry 
between human and bacterial PDC-E2 [24,25]. Therefore, environmental factors such 
as microorganisms and xenobiotics are speculated to disrupt the self-tolerance to 
autoantigens as a specific intrahepatic BEC malfunction, supporting the forementioned 
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role of PAMPs in the etiopathogenesis of PBC. 
Biliary atresia: Biliary atresia consists of a fetal type affecting 10-25% of 
patients, and the more common perinatal type. The perinatal type is characterized by a 
progressive, inflammatory, and sclerosing cholangiopathy. The presence of several 
viruses including Reoviridae (type 3 reovirus and type C rotavirus) (Table 1) in liver 
tissue or affected bile duct specimens obtained from patients with biliary atresia 
during the Kasai procedure or a liver transplantation, has been demonstrated 
[13,26-31], though conflicting results have been reported [13,26,28-30,32]. 
Immunostaining for Mx proteins, which mediate an early innate immune response and 
are highly sensitive markers for type I interferon (IFN) activity, revealed that 
hepatocytes and intrahepatic bile ducts in biliary atresia are positive for Mx, 
suggesting the presence of viruses in hepatocytes and biliary epithelial cells of patients 
with biliary atresia [33]. Among these viruses, Reoviridae having a double-stranded 
RNA (dsRNA) genome, in particular, are characterized by epithelial tropism, and 
rotavirus type A is the most frequent etiological agent in cases of acute infantile 
diarrhea in young children. Moreover, the infection of newborn Balb/c-mice with 
Reoviridae including type A rhesus rotavirus (RRV) and type 3 reovirus (Abney) leads 
to a cholestasis and biliary obstruction resembling human biliary atresia [34,35]. 
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Therefore, it is likely that BECs are a target of these viruses which directly cause the 
cholangiopathy in cases of biliary atresia. 
Hepatolithiasis: Hepatolithiasis is not a rare disease in East Asian countries 
including Japan and is characterized by the formation of stones and histologically 
"chronic proliferative cholangitis". Bacterial infections in the biliary tree and 
cholestasis have been implicated as the major etiopathogenic factor for lithogenesis in 
patients with calcium-bilirubinate stones. Escherichia coli (E.coli) is the bacterium 
most frequently isolated, followed by several species shown to have β-glucuronidase 
(Table 1). Moreover, the presence of Campylobacter species-specific DNA has been 
demonstrated in bile samples and biliary mucosa specimens in cases of hepatolithiasis, 
by PCR (Table 1) [9]. These bacteria in the biliary epithelium are speculated to 
influence the occurrence and development of cholangitis and lithogenesis, though the 
mechanism of such an effect is still unclear. 
 
Basic mechanisms of biliary innate immunity 
BECs are immunologically potent cells. The BECs of inflamed bile ducts 
actively participate in the inflammation by secreting cytokines and expressing immune 
receptors. In addition to immunocompetent cells, epithelial cells including BECs 
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recognize microbes and their constituents via a set of receptors, referred to as 
pattern-recognition receptors (PRRs). TLRs are the major epithelial PRRs recognizing 
PAMPs. Ten TLRs (TLR1 to TLR10) have been identified in humans, with TLR4 
known to mediate inflammatory responses to LPS. In immunocompetent cells, the 
response to LPS is mediated by interaction with the TLR4 in conjunction with TLR4 
accessory proteins MD-2 and CD14, triggering transduction of intracellular signals 
followed by the activation of TLR-associated adapter proteins, myeloid differentiation 
factor 88 (MyD88) and IL-1 receptor-associated kinase (IRAK)-1, leading to the 
activation of nuclear factor-κB (NF-κB) and then to the synthesis of antibiotics and 
proinflammatory cytokines. In contrast to bacterial PAMPs, dsRNA viruses such as 
Reoviridaes (reovirus and rotavirus) are recognized by TLR3, IFN-inducible helicase 
retinoic acid-induced protein I (RIG-I), and melanoma differentiation-associated 
gene-5 (MDA-5). The stimulation of these receptors by dsRNA transduces signals to 
activate the transcription factor interferon regulatory factor 3 (IRF3) as well as NF-κB. 
Human and murine BECs possess at least TLR1-TLR5, related molecules (MD-2, 
MyD88, and IRAK-1), RIG-I, and MDA-5 [4,36-38]. Moreover, 
immunohistochemistry has confirmed that TLR1-TLR5, MyD88 and IRAK-1 are 
distributed diffusely in the intrahepatic biliary tree of normal human liver, irrespective 
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of anatomical levels [38] (Fig.1). In addition to the expression of these receptors, the 
responsiveness of BECs to the corresponding PAMPs is also found. For example, LPS 
binds to the surface of cultured BECs, and induces the production of TNF-α mRNA in 
an NF-κB-dependent manner [4]. Moreover, stimulation with 
polyinosinic-polycytidylic acid (poly(I:C), a synthetic analog of viral dsRNA) induces 
the activation of NF-κB and IRF3 and the production of IFN-1 and MxA as potent 
antiviral responses [37]. Therefore, BECs possess functional TLR signaling systems 
and participate in innate immunity. 
 
Chemical mediators produced by a biliary innate immune response 
Innate immunity provides defense against bacterial and viral infections. 
Therefore, as part of an innate immune response, several antibiotics are produced. 
Cytokines and chemokines are also produced in immunocompetent cells and play an 
important role in subsequent acquired immunity. Moreover, BECs have been shown to 
secrete polymeric immunoglobulin A, several antibiotics against bacteria (lactoferrin, 
lysozyme, and defensins) and viruses (IFN-1 and MxA), cytokines, and chemokines 
on treatment with PAMPs, thereby contributing to biliary mucosal defense and 
subsequent acquired immunity [39-41]. 
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Defensin: Defensins are antimicrobial peptides identified as key elements in 
innate immunity. Structurally, they are divided into α- and β-defensins. The β-defensin 
family is distributed in the epithelium of several organs, constituting an important 
barrier at mucosal surfaces. So far, human β-defensins (hBD-1 to -6) have been 
identified.  hBD-1 is constitutively expressed in cultured BECs and diffusely 
distributed in the cytoplasm of intrahepatic bile ducts irrespective of anatomical levels 
[42] (Fig.2). Moreover, because hBD-1 is constantly detectable in bile samples, hBD-1 
it is believed to play a role in the constitutive antimicrobial defense of the 
hepatobiliary system [42]. This may be why biliary tract infections are rare and bile is 
sterile under physiological conditions, though the biliary tree is potentially exposed to 
enteric bacteria. In contrast, hBD-2 is not detected in BECs cultured without a 
stimulant, but de novo expression is found in LPS- or E.coli-treated BECs. In vivo, 
hBD-2 expression is restricted to the intrahepatic large bile ducts and peribiliary 
glands, in particular, showing cholangitis in extrahepatic biliary obstruction and 
hepatolithiasis (Fig.2) [42]. Because in these diseased livers, enteric bacteria are 
mostly cultivable in bile, the participation of bacteria-related cholangitis is closely 
associated with the hBD-2 expression in BECs. hBD-1 plays a constitutive role in 
biliary antimicrobial defense, while hBD-2 expression is induced in response to local 
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infections and may play a role in additional antimicrobial defenses. 
Interleukin 8: IL-8 is a major cytokine of neutrophils, and functions not only 
as a chemoattractant of neutrophils, basophiles, and some populations of T cells, but 
also as an activator of neutrophils for releasing leukotrienes, activated oxygen, and 
neutrophil defensins. Bacteria or their products have been reported to induce the 
secretion of IL-8 from intestinal or gingival epithelial cells, and such cytokines and 
chemokines are speculated to be involved in epithelial cell damage during bacterial or 
fungal infections. Cultured human BECs express and release IL-8 in response to 
bacterial PAMPs including LPS [43]. IL-8 expression is found in proliferating bile 
ductules in various diseased livers and closely associated with neutrophilic infiltration 
[43]. Particularly cholangitis lenta defined as bile ductular proliferation, ductular 
cholestasis, and ductular epithelial damage, is also accompanied by a prominent 
neutrophilic infiltration [44]. Cholangitis lenta is usually encountered in septic 
conditions, so circulating infectious reagents such as bacterial toxins or products, 
cytokines, or chemokines are speculated to be involved in its pathogenesis. In a state 
of sepsis, particularly endotoxemia, BECs may secrete IL-8 and attract neutrophils to 
reactive bile ductules. IL-8 produced in bile ductular biliary epithelia is a potential 
target in the prevention of liver and biliary damage in diseased livers such as septic 
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liver. 
Fractalkine: Fractalkine (CX3CL1) is a chemokine with both 
chemoattractant and cell-adhesive functions and plays an important role in the 
migration of leukocytes to target sites under physiological as well as pathological 
conditions. Fractalkine is expressed in several epithelial cells under normal conditions 
and involved in the chemoattraction to the epithelial layer and adhesion of 
mononuclear cells expressing its receptor, CX3CR1. The fractalkine level elevated in 
serum concurrent with increased expression of CX3CR1 in liver-infiltrating 
mononuclear cells in patients with PBC [45], suggesting fractalkine to be critical for 
the generation and persistence of the portal lymphocytic infiltration in PBC. In fact, 
fractalkine is detectable in BECs of small bile ducts in normal and diseased livers, but 
it is increased in injured bile ducts of PBC [45]. Moreover, many CX3CR1-positive 
mononuclear cells infiltrate into portal tracts and most biliary intraepithelial 
lymphocytes in injured bile ducts are also positive for CX3CR1. Production of 
fractalkine in BECs is responsible for the chemoattraction of CX3CR1-positive 
lymphocytes into portal tracts and into biliary epithelia [45]. Recently, Shimoda et al 
[46] demonstrated the significance of fractalkine and the precise mechanism of its 
production using populations of multiple intrahepatic cell types, including endothelial 
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cells, liver sinusoidal endothelial cells, and BECs, to directly study the interaction of 
fractalkine-producing cells with liver-infiltrating mononuclear cells. Endothelial cells 
produced large amounts of fractalkine upon stimulation by PAMPs, though liver 
sinusoidal endothelial cells produced no fractalkine. Moreover, BECs also produced 
fractalkine; TLR3-stimulated BECs produced fractalkine after direct contact with 
TLR4-stimulated autologous monocytes. Innate immunity may lead to increased 
expression of fractalkine in the liver and contribute to the development of 
cholangiopathy in cases of PBC. 
 
Tolerance 
The luminal surface of the biliary tree is continually exposed to PAMPs via 
bile and/or portal blood, but no inflammatory response is elicited in BECs. This lack 
of response to PAMPs, especially LPS, could be due to "endotoxin tolerance," an 
important mechanism of maintaining the homeostasis of organs such as the intestines 
which have commensal bacterial flora and to avoid excessive tissue damage [47]. In 
addition to intestinal epithelial cells, BECs possess similar tolerance; treatment with 
LPS for 24hrs significantly induced tolerance to a subsequent exposure to LPS as 
assessed by measuring levels of NF-κB activity and TNF-α mRNA production in 
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cultured BEC cells (Fig.3) [48]. Moreover, pretreatment with Pam3CSK4 (TLR1/2 
ligand) effectively induced tolerance to subsequent stimulation with LPS (TLR4 
ligand) (Fig.3) [48]. This cross-tolerance has been demonstrated in monocytes and 
intestinal epithelial cells [47]. However, treatment with poly(I:C) (TLR3 ligand) 
significantly enhanced NF-κB activity in fresh cultured BECs and pretreatment did not 
lead to tolerance to poly(I:C) (Fig.3) [49]. Levels of production of MxA and TRAIL 
were also preserved. Therefore, tolerance to a TLR3 ligand (poly(I:C)) is not found in 
BECs. 
In response to LPS, the structural complex formed by myeloid differentiation 
factor 88 (MyD88), IL-1 receptor-associated kinase (IRAK)-1, IRAK-4, and TNF 
receptor-associated factor 6 (TRAF6) induces a series of phosphorylation events, 
leading to the activation of nuclear transcription factors. IRAK-M plays a critical 
negative regulatory role in the signaling between MyD88 and IRAK-1 [50]. In 
LPS-tolerant cultured BECs, levels of the IRAK-M mRNA and protein were increased, 
implying that the expression of IRAK-M interferes with the association between 
IRAK-1 and MyD88 and is crucial to the LPS-induced tolerance of endotoxin in BECs 
[48]. Moreover, Pam3CSK4 as well as LPS induced IRAK-M expression in BECs [48], 
suggesting that the tolerance caused by the up-regulation of IRAK-M expression is 
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also associated with cross-tolerance to LPS induced by Pam3CSK4. 
Immunohistochemically, IRAK-M was constitutively expressed in the cytoplasm of 
BECs, irrespective of intrahepatic biliary levels (Fig.4). This finding suggests that the 
expression of IRAK-M is associated with hypo- or un-responsiveness to bacterial 
PAMPs in bile and/or portal flow. In contrast, although IRAK-M mRNA expression 
was upregulated by stimulation with dsRNA (TLR3 ligand), no tolerance to the 
dsRNA was found in cultured BECs. This is reasonable because the intracellular 
signaling of dsRNA-related receptors is a MyD88-independent pathway, that is, the 
dsRNA-related response is not affected by IRAK-M [51]. Moreover, the upregulation 
of IRAK-M expression on treatment with poly(I:C) is speculated to cause 
dsRNA-stimulated BECs to become tolerant to TLR2- and TLR3-related PAMPs 
including LPS. However, BECs are speculated to be in an entirely virus-free state and 
at the time of infection of a dsRNA virus, an innate response to dsRNA develops and 
continues in the presence of virus in the biliary tree, suggesting that the infection 
likely causes progressive destruction in the biliary epithelium without inducing 
tolerance. 
 
Cholangiopathy associated with biliary innate immunity 
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Cell death: BECs lining the biliary tree are tolerant of non-pathogenic 
commensal bacterial PAMPs so as to maintain the homeostasis of biliary innate 
immunity under physiological conditions. Even though biliary innate immunity is 
activated by pathological PAMPs and provides ‘danger signals’ to the biliary tree, 
more effective negative mechanisms occur to avoid tissue damage.  
However, because innate immune tolerance of dsRNA is lacking in BECs, 
cell and tissue damage is found in the biliary innate immune response via TLR3 [49]. 
Stimulation with poly(I:C) induced the activation of NF-κB and IRF-3, followed by 
the production of antiviral IFN-1 [37] and also enhanced apoptosis via production of 
tumor necrosis factor-related apoptosis-inducing ligand (TRAIL).[37] Moreover, in 
biliary atresia in which Reoviridae are speculated to be an etiological agent, BECs 
lining extrahepatic bile ducts diffusely and constantly expressed TLR3 and showed an 
enhancement of TRAIL and single-stranded DNA (ssDNA)-positive apoptosis as well 
as the activation of NF-κB and IRF-3 and increased expression of an anti-viral product, 
MxA [33,37,38]. Therefore, BECs not only directly participate in the antiviral innate 
immune response through the production of antiviral effectors to prevent viral 
replication by secreting antibiotics in response to dsRNA, but also play a role in the 
generation of apoptotic responses to infected cells. This additional mechanism 
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concerning cell death in biliary innate immunity is directly associated with the 
pathogenesis of cholangiopathies in biliary atresia. 
Epithelial-mesenchymal transition (EMT): Fundamental to EMT is a loss 
of normal epithelial features such as cell-to-cell adhesion molecules and the gain of a 
mesenchymal phenotype [52]. Recently, the EMT of BECs has been speculated to be 
associated with periductal fibrosis and portal fibrosis in several chronic hepatobiliary 
diseases [53-56]. In biliary atresia, in particular, the mesenchymal markers vimentin 
and S100A4 (also known as fibroblast-specific protein 1), and an essential 
transcription factor for EMT, Snail, are expressed but the biliary-type cytokeratin 
CK19 and the common epithelial marker E-cadherin are not, in BECs of extrahepatic 
bile ducts and peribiliary glands. The occurrence of EMT in the BECs of these 
anatomical biliary components is closely associated with the pathogenesis of 
sclerosing cholangiopathy in biliary atresia [56,57]. As mentioned, although the biliary 
innate immune response to dsRNA reduces the viability of cultured human BECs via 
TRAIL-mediated apoptosis, the rate of cell death is approximately 30% [37]. The cells 
that evade apoptosis show a gradual loss of CK19 and E-cadherin, and increased 
expression of S100A4 and Snail, demonstrating the occurrence of biliary EMT. 
Because EMT confers resistance to apoptotic effects in fetal rat hepatocytes [58], 
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biliary EMT is thought to be a survival mechanism and associated with an incomplete 
induction of apoptosis caused by the biliary innate immune response.  
TGF-β1 and basic fibroblast growth factor (bFGF) are the major inducers of 
EMT and TGF-β1 plays an important role in the initiation and progression of liver 
fibrosis [59,60]. Moreover, because expression of the TGF-β1 pseudoreceptor, bone 
morphogenic protein and activin membrane-bound inhibitor (Bambi), is decreased by 
an innate immune response and consequently, susceptibility to TGF-β1 is increased, 
loss of Bambi and upregulation of the TGF-β receptor are also speculated to be 
inducers of EMT [61]. Cultured human BECs constantly express TGF-β1, its receptor 
TGFβR1, and the bFGF receptor (FGFR1) [54,57]. However, because Bambi is also 
expressed in BECs, the induction of EMT is likely inhibited by the effect of Bambi. 
Treatment with poly(I:C) gradually decreases and increases the expression of Bambi 
and bFGF, respectively, and stimulation with bFGF quickly induces a reduction in the 
level of Bambi. Therefore, the biliary innate immune response to dsRNA could 
increase susceptibility to TGF-β1, and both TGF-β and bFGF play important roles in 
the biliary EMT induced by a dsRNA-related innate immune response. 
Chronic inflammation: Recently, in addition to Th1 and Th2 cells, a third 
type of pathogenic helper T cell, the Th17 cell, and its association with the chronic 
             HARADA, et al.  - 19 - 
inflammation of autoimmune diseases, has been noted [62]. Human Th17 cells are 
characterized by the production of interleukin (IL)-17 (IL-17A and IL-17F) and 
differentiate from naïve T cells (Th0). Th17 cells are part of the mucosal host defense 
system and have a major role in protection against bacterial infections. Moreover, with 
the discovery that Th17 cells are also involved in the pathogenesis of chronic 
inflammatory disorders including models of some autoimmune diseases, there has 
been intense interest in the relative contributions of Th17 and Th1/Th2 cells to the 
pathogenesis of these diseases. In liver, IL-17-positive cells identified as Th17 cells 
are mainly present at the interface of inflammed portal tracts in cases of PBC and 
CVH-C, and also, in PBC, accumulated around damaged interlobular bile ducts [63]. 
Th17 cells are associated with interface hepatitis in chronic liver diseases. Moreover, 
the Th17-related peribiliary cytokine milieu is enhanced in PBC and implicated in the 
histogenesis of the sustained cholangitis of PBC. 
In human Th17 cells, IL-6 and IL-1 are required for differentiation [64], 
while IL-23 is necessary for maintaining or stabilizing cellular functions and survival, 
but not differentiation [62]. Bacterial PAMPs including LPS cause the production of 
Th17-inducible cytokines (IL-6 and IL-1β) and a Th17-maintaining cytokine (IL-23) 
in cultured BECs [63]. Moreover, BECs lining damaged bile ducts in PBC, express 
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IL-6, IL-1β, and IL-23 p19 [63]. The biliary innate immune response to bacterial 
components involves the production of Th17-inducible and -maintaining cytokines in 
BECs and also the differentiation into Th17 cells of periductal dendritic cells and 
macrophages. Biliary innate immunity plays a role in the induction and maintenance 
of Th17 cells in the periductal area in cases of PBC. 
  
Modulation of biliary innate immunity as a therapeutic strategy 
Therapeutic strategies have been proposed for the modulation of hepatic 
innate immunity, but rarely for biliary innate immunity. Peroxisome 
proliferator-activated receptor γ (PPARγ) is a nuclear receptor involved in regulating 
adipocyte differentiation and also anti-inflammatory activities [65]. The activation of 
PPARγ by its ligands is shown to inhibit the expression of pro-inflammatory cytokines 
such as TNF-α, the induction of which is mediated via NF-κB [66]. In liver, PPARγ is 
constitutively expressed in intrahepatic bile ducts, irrespective of the anatomical level 
(Fig.5), and may relate to the maintenance of biliary homeostasis and absence of 
inflammatory reactions by attenuating inflammatory signals in BECs to PAMPs [67]. 
In PBC liver, PPARγ expression is significantly down-regulated in the affected bile 
ducts (Fig.5), indicating an increased susceptibility to PAMPs. IL-4 (Th2 cytokine) 
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and IFN-γ (Th1 cytokine) up- and down-regulate PPARγ expression, respectively, in 
cultured human BECs. An unique cytokine milieu is associated with the reduction in 
PPARγ expression in the affected bile ducts of PBC liver [67]. 
Several PPARγ ligands have been identified, including the prostaglandin D 
metabolite 15-deoxy-Δ12,14-prostaglandin J2 (15d-PGJ2) and thiazolidinedione 
derivatives. 15d-PGJ2 functions as an endogenous ligand for PPARγ and attenuates 
the activation of NF-κB by preventing the phosphorylation of its inhibitor protein 
(I-κB). In cultured human BECs, 15d-PGJ2 treatment attenuates PAMP (LPS or 
peptidoglycan)-induced NF-κB activation and also TNF-α production (Fig.6). PPARγ 
ligands provide protection against biliary inflammation in PBC, but 15d-PGJ2 
inhibited NF-κB’s activation independent of PPARγ [67,68]. In fact, a PPARγ 
antagonist (GW9662) partially blocked the inhibitory effects of 15d-PGJ2 on NF-κB 
activity. Therefore, 15d-PGJ2 is expected to be effective in the anti-inflammatory 
treatment of bile ducts with reduced as well as preserved PPARγ expression in PBC. 
Because PPARγ is a key immunomodulatory molecule, a reduction in its expression in 
the bile ducts of PBC liver may be important to the immunopathogenesis of chronic 
cholangitis. Therefore, immunosuppression using PPARγ ligands may help to reduce 
bile duct damage in PBC.  
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Conclusion   
Biliary innate immunity consisting of an organ-specific system is important 
for the mucosal immunity in intrahepatic and extrahepatic bile ducts. Biliary innate 
immunity is surely associated with the pathogenesis of biliary diseases as well as 
defense against microbial infections. The molecular mechanisms involved have 
recently been clarified. Targeting of NF-κB is thought to be a potential therapeutic 
strategy in various cells, but TLR signaling-specific molecules are also likely to be 
suitable molecular targets. Further translational research concerning the regulation of 
biliary innate immunity is needed. 
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Table 1   Bacteria and viruses possible etiological of biliary diseases 
 
Primary biliary cirrhosis 
・Detection of microorganisms 
    - lipopolysaccharide (LPS) 
    - lipoteichoic acid  
    - Helicobacter   
    - -retrovirus 
    - P.acnes 
   
・Molecular mimicry between human and microbial PDC-E2 
   - E.coli 
    - Mycobacterium 
     - Novosphingobium 
     - Lactobacillus 
     - Chlamydia 
 
Biliary atresia  
- Reovirus 
- Rotavirus 
- cytomegalovirus (CMV) 
- adenovirus 
- enterovirus 
- Ebstein-Barr virus (EBV) 
 
Primary sclerosing cholangitis 
   - Helicobacter 
- a-hemolytic streptococcus 
 
Hepatolithiasis 
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Fig.1   
 
Representative expression pattern of TLR4 in interlobular bile ducts.  Membranous 
(mainly lateral) in addition to weakly cytoplasmic expression is found in Primary biliary 
cirrhosis. Immunohistochemistry for TLR4. 
 
 
             HARADA, et al.  - 32 - 




Immunohistochemical staining for human beta defensin (hBD)-1 (A) and hBD-2 (B). 
(A) Normal liver. Septal bile ducts are positive for hBD-1. (B) Extrahepatic biliary 
obstruction. Biliary epithelium of the intrahepatic large bile duct showing cholangitis 
strongly expresses hBD-2.  
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Fig.3 
 
Induction of tolerance in cultured human biliary epithelial cells (BECs). BECs are 
pretreated with lipopolysaccharide (LPS, TLR4 ligand) or Pam3CSK4 (Pam3, TLR1/2 
ligand) for 24h and subjected to another LPS challenge. Pretreatment with LPS and 
Pam3CSK4 significantly decreases NF-κB activity in response to a subsequent LPS 
challenge. In contrast, the pretreatment with poly(I:C) (TLR3 ligand) or LPS does not 
inhibit NF-κB’s activation in response to a subsequent poly(I:C) challenge (*<0.05). 
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Fig.4 
 
IRAK-M is constitutively expressed in the cytoplasm of septal bile ducts in normal liver. 
Immunohistochemistry for IRAK-M. 




Immunohistochemistry for peroxisome proliferator-activated receptor γ（PPARγ）A: 
Normal liver. PPARγ is expressed in the cytoplasm of bile ducts (arrow). B: Primary 
biliary cirrhosis (PBC). Damaged bile ducts (arrowhead) show reduced expression of 
PPARγ, though evidently positive biliary cells (arrow) also remain. 
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Fig.6 
 
Effect of the peroxisome proliferator-activated receptor γ (PPARγ) ligand, 15d-PGJ2, on 
lipopolysaccharide (LPS, TLR4 ligand)- and peptidoglycan (TLR2 ligand)-induced 
NF-κB activation in cultured human biliary epithelial cells (BECs). BECs are pretreated 
in the presence or absence of 15d-PGJ2 (20μM) before stimulation with LPS or 
peptidoglycan. Pretreatment with 15d-PGJ2 significantly prevents PAMP-induced 
NF-κB activation (*<0.05).  
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